logo

NBIX

Neurocrine Biosciences·NASDAQ
--
--(--)
--
--(--)
3.76 / 10
Netural

NBIX's fundamental status is lackluster with a 3.8/10 score. Key weaknesses include a high PB-ROE value of 2.2098, indicating potential overvaluation relative to peers, while moderate YoY revenue growth of 18.95% and a solid interest-coverage ratio of 15.48 offer some support. Days sales outstanding at 79.2985 suggest slower receivable collection, offsetting otherwise healthy liquidity. Overall, the fundamental picture calls for cautious positioning.

Fundamental(3.76)SentimentTechnical

Analysis Checks(9/10)

Revenue-MV
Value-0.52
Score3/3
Weight20.96%
1M Return10.54%
Total operating revenue (YoY growth rate %)
Value18.95
Score2/3
Weight1.79%
1M Return1.11%
Days sales outstanding
Value79.30
Score2/3
Weight1.82%
1M Return1.10%
Profit-MV
Value0.22
Score2/3
Weight16.71%
1M Return8.45%
Net income-Revenue
Value0.76
Score2/3
Weight16.73%
1M Return8.45%
PB-ROE
Value2.21
Score0/3
Weight4.99%
1M Return2.72%
Interest coverage ratio (EBIT / Interest expense) (%)
Value15.48
Score2/3
Weight-1.67%
1M Return-1.11%
Operating revenue (YoY growth rate %)
Value18.95
Score2/3
Weight0.69%
1M Return0.43%
Asset-MV
Value-0.50
Score2/3
Weight21.55%
1M Return10.15%
Cash-MV
Value-0.27
Score2/3
Weight16.43%
1M Return8.41%
Is NBIX undervalued or overvalued?
  • NBIX scores 3.76/10 on fundamentals and holds a Fair valuation at present. Backed by its 11.62% ROE, 15.95% net margin, 32.89 P/E ratio, 4.69 P/B ratio, and 10.82% earnings growth, these metrics solidify its Netural investment rating.